Home Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy
Article Open Access

Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy

  • Mengxue Mei , Ming Fang , Ye Mao , He Chen and Long Huang EMAIL logo
Published/Copyright: March 8, 2023

Abstract

Previous studies suggest that baclofen may be useful in the treatment of intractable hiccup caused by chemotherapy. This study was aimed to assess the possible efficacy and safety of baclofen. In total, 65 patients with intractable hiccup caused by chemotherapy were screened. 45 patients with intractable hiccup caused by chemotherapy were finally recruited. Participants in the trial received 10 mg baclofen three times daily for 3 days. The primary outcome measure was cessation of hiccups. Secondary outcome measures included efficacy and adverse events. All 45 patients completed the study. Among them, 41 cases were cured (91.11%, 41/45), 4 cases were relieved (8.89%, 4/45), and the overall effective rate was 100% (45/45). Furthermore, the median remission time was 2(1, 9) times, the median cure time was 2(1, 9) times, the remission rate of one-time was 13.33% (6/45), the remission rate of two-time was 53.33% (24/45), and 2 cases (4.44%, 2/45) relapsed after drug withdrawal. No serious adverse events were documented. Only 1 case (2.22%) had grade 2 fatigue and 2 cases (4.44%) had grade 1 sleepiness. Baclofen is safe and effective in the treatment of intractable hiccup caused by chemotherapy of malignant tumor.

1 Introduction

Chemotherapy is an important means to treat malignant tumors. Common chemotherapy drugs include cisplatin, paclitaxel, etc. Cisplatin can combine with the DNA of tumor cells, causing cross-linking, thus destroying the DNA function of tumor cells and inhibiting and killing the proliferation of tumor cells. Paclitaxel can break the balance of tubulin and tubulin dimer, induce and promote tubulin polymerization, thus stabilizing microtubules, inhibiting tumor cell division and triggering cell apoptosis [1]. However, chemotherapy drugs can not only kill cancer cells, but also damage normal cells, leading to chemotherapy side effects in patients [2].

Hiccup is a common side effect of chemotherapy in clinic, mainly due to stimulation of central nervous system, which leads to paroxysmal spasm of unilateral or bilateral diaphragm. According to previous findings, about 2% of patients with malignant tumors have intractable hiccups during chemotherapy, and most patients will have symptoms such as dyspnea, vomiting, and nausea, which will affect the chemotherapy effect [3]. At present, clinically, intractable hiccups are usually treated with gastric motility drugs and sedative drugs, such as metoclopramide and chlorpromazine, among which metoclopramide is a dopamine D2 receptor antagonist, which can act on dopamine receptors in the emetic chemoreceptor area of the medulla oblongata and raise the threshold. At the same time, it can also directly inhibit the chemosensory area of medulla oblongata, and reduce the excitatory impulse to diaphragm [4,5]. Chlorpromazine belongs to the first generation of phenothiazine antipsychotics, which can block the dopamine receptor in the cerebral cortex pathway of midbrain limbic diseases and inhibit the dopamine receptor in the chemically sensitive area of medulla oblongata, so as to inhibit vomiting center, produce anti-emesis effect, and improve the clinical symptoms of patients [6]. However, due to the great differences in clinical individuals, different curative effects, long drug onset time, and high risk of adverse reactions, the clinical treatment effect is average. Therefore, it is still necessary to actively explore the treatment scheme that can effectively improve the intractable hiccup caused by chemotherapy for malignant tumors.

Caffeine belongs to nervous system medicine, which is a muscle relaxant acting on the spinal cord and has a positive effect on relieving reflex muscle spasm [7]. Baclofen is effective in treating refractory gastroesophageal reflux cough, which can effectively relieve clinical symptoms [8]. At present, FDA and CFDA have not approved baclofen’s indication for treating intractable hiccup caused by chemotherapy of malignant tumor. In view of this, this study will analyze the feasibility of baclofen in treating intractable hiccup caused by chemotherapy of malignant tumor from the aspects of therapeutic effect and safety.

2 Methods

2.1 Study population

In this study, 65 patients with intractable hiccup caused by chemotherapy of malignant tumor were screened from July 2020 to July 2022. Because of severe complications shown in the exclusion criteria and potential confounding factors of intractable hiccup, 20 candidates were excluded from the study, and the remaining 45 patients were included in this study. There were 44 males and 1 female. The median age is 64 (37,75) years; PS score 0–2 points. Types of malignant tumors: 11 cases of liver cancer, 10 cases of lung cancer, 7 cases of colorectal cancer, 4 cases of gastric cancer, 3 cases of esophageal cancer, 2 cases of nasopharyngeal cancer, 1 case of spinal cord tumor, 1 case of glioblastoma, 1 case of thymic adenocarcinoma, 1 case of laryngeal phosphorus cancer, 1 case of pancreatic cancer, 1 case of isthmus carcinoma, 1 case of bladder carcinoma, and 1 case of maxillary sinus carcinoma. Hiccup nature: 30 cases were persistent and 15 cases were intermittent. Severity of hiccup: severe in 19 cases, moderate in 17 cases, and mild in 9 cases. Complications: vomiting in 27 cases and sleep disorder in 22 cases. The median period of intractable hiccup is 1 (1,15). There were 36 cases of first-line chemotherapy, 3 cases of second-line chemotherapy, 4 cases of third-line chemotherapy, and 2 others. Intravenous chemotherapy was used in 35 cases, interventional chemotherapy in 6 cases, and oral chemotherapy in 4 cases. The median time from chemotherapy to hiccup was 21.00 h (12.00 h, 24.00 h).

Inclusion criteria: (1) Malignant tumors were all confirmed by pathological examination; (2) Intractable hiccup meets the relevant diagnostic criteria, namely, hiccups lasting longer than 1 month [9]; (3) All patients received chemotherapy; (4) Hiccup occurred newly within 24 h after chemotherapy; (5) Physical condition (PS) score [10]: 0–2 points; (6) Signed informed consent form. Exclusion criteria: (1) Patients complicated with severe cardiac and pulmonary insufficiency; (2) Those complicated with gastrointestinal bleeding; (3) Those with coagulation dysfunction; (4) Those complicated with severe liver and renal dysfunction; (5) Intractable hiccup caused by other factors, such as cerebral infarction and brain trauma; (6) Those with combined blood diseases. Written informed consent was obtained from all patients. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University, and conducted according to the Declaration of Helsinki.

2.2 Treatment

The patients were treated with baclofen tablets (Ningbo Tianheng Pharmaceutical Co., Ltd, Fu’an Pharmaceutical Group, specifications: 10 mg*10 s, GuoYaoZhunZi H19980103) when hiccup occurred newly within 24 h after chemotherapy, at 10 mg/time, 3 times/day orally for 3 days. The daily dosage and frequency of baclofen were determined according to the published results and real-world clinical use [11]. During the treatment, no other mediations or treatments were received among patients.

2.3 Study outcomes

(1) Clinical efficacy: Cure: the hiccup completely stopped 3 days after treatment. Remission: the attack times of hiccup were obviously reduced, which is more than 50% lower than that before treatment. Invalid: the above criteria are not met or the disease aggravates [12]. Total effective rate = (cured + relieved) cases/total cases × 100%. The patient’s median response time, the median cure time, and the one-time medication response rate were recorded. (2) Adverse reactions and recurrence: adverse reactions including fatigue (conscious fatigue and limb weakness), drowsiness (excessive daytime sleep or sleep onset), tremors (rhythmic and alternating swinging movements), and hiccup recurrence after drug discontinuation were recorded during the treatment.

2.4 Statistical analysis

SPSS 25.0 software was used, and GraphPad Prism 8.0 software was used to draw the patient’s medication times and remission after medication.

3 Results

3.1 Clinical efficacy

All the 45 patients completed the treatment according to the plan. There were 41 cured cases (91.11%), 4 relieved cases (8.89%), and the total effective rate was 100% (45/45). The improvement rates of one-time medication and two-time medication were 13.33% (6/45) and 53.33% (24/45), respectively. The median response time was 2 (1,9) times, and the median cure time of 41 cured patients was 2 (1,9) times (Table 1, Figure 1).

Table 1

Baseline data and treatment of patients

Patient number Age Disease Chemotherapy regimens Degree of hiccup Optimal efficacy of baclofen Medication times for achieving optimal curative effect Median times for response to baclofen
1 67 Lung cancer Etoposide + carboplatin Moderate Cure 2 1
2 37 Gastric cancer Paclitaxel + S-1 Serious Cure 5 2
3 34 Spinal cord tumor Temozolomide Moderate Cure 7 3
4 65 Gastric cancer Oxaliplatin + paclitaxel + S-1 Mild Alleviate 8 2
5 67 Gastric cancer Docetaxel + 5-fu + oxaliplatin Serious Alleviate 8 2
6 46 Glioblastoma Temozolomide Moderate Alleviate 6 2
7 69 Esophageal cancer S-1 Mild Cure 8 2
8 69 Liver cancer Ifosfamide + doxorubicin Serious Cure 2 1
9 57 Liver cancer Oxaliplatin + 5-fu Serious Cure 4 2
10 56 Lung cancer Pemetrexed + cisplatin Serious Cure 5 1
11 64 Lung cancer Pemetrexed Mild Cure 2 1
12 57 Lung cancer Paclitaxel Moderate Cure 2 2
13 65 Lung cancer Etoposide + carboplatin Moderate Cure 1 1
14 62 Esophageal cancer Paclitaxel + carboplatin Mild Cure 1 1
15 69 Lung cancer Paclitaxel + nedaplatin Moderate Cure 3 2
16 64 Thymic adenocarcinoma S-1 Serious Cure 7 2
17 74 Laryngocarcinoma Docetaxel + nedaplatin Moderate Cure 2 1
18 22 Liver cancer Oxaliplatin + 5-fu + pirarubicin Moderate Alleviate 9 3
19 53 Liver cancer Oxaliplatin + 5-fu + pirarubicin Serious Cure 2 1
20 42 Nasopharyngeal cancer Paclitaxel + nedaplatin Mild Cure 1 1
21 50 Nasopharyngeal cancer Paclitaxel + nedaplatin Mild Cure 2 1
22 64 Liver cancer Gemcitabine + cisplatin Serious Cure 5 2
23 58 Lung cancer Docetaxel Moderate Cure 2 1
24 72 Colorectal cancer Oxaliplatin + 5-fu + bevacizumab Moderate Cure 2 2
25 65 Pancreatic cancer Paclitaxel + Gemcitabine Moderate Cure 9 1
26 54 Colorectal cancer Oxaliplatin + irinotecan + 5-fu Mild Cure 2 2
27 58 Colorectal cancer Oxaliplatin + 5-fu + bevacizumab Serious Cure 2 1
28 53 Isthmus carcinoma Docetaxel + nedaplatin Serious Cure 7 4
29 68 Bladder carcinoma Paclitaxel + Tirelizumab Serious Cure 6 3
30 71 Colorectal cancer Oxaliplatin + 5-fu + bevacizumab Serious Cure 4 2
31 42 Liver cancer Oxaliplatin + 5-fu + pirarubicin Serious Cure 4 3
32 73 Liver cancer Oxaliplatin + 5-fu + pirarubicin Moderate Cure 5 2
33 75 Colorectal cancer Oxaliplatin + capecitabine Moderate Cure 2 1
34 68 Esophageal cancer Paclitaxel Moderate Cure 1 1
35 72 Liver cancer Oxaliplatin + 5-fu + pirarubicin Mild Cure 8 2
36 64 Lung cancer Etoposide + Carboplatin Serious Cure 3 1
37 63 Maxillary sinus tumor Doxorubicin + cyclophosphamide Serious Cure 1 1
38 65 Colorectal cancer Oxaliplatin + 5-fu Serious Cure 3 2
39 65 Liver cancer Oxaliplatin + 5-fu + pirarubicin Serious Cure 2 1
40 68 Liver cancer Oxaliplatin + 5-fu + pirarubicin Mild Cure 2 1
41 58 Lung cancer Paclitaxel + carboplatin Serious Cure 2 2
42 75 Lung cancer Paclitaxel + carboplatin Moderate Cure 2 1
43 72 Colorectal cancer Irinotecan + 5-fu + Bevacizumab Moderate Cure 2 1
44 69 Gastric cancer Oxaliplatin + capecitabine Moderate Cure 1 2
45 58 Liver cancer Oxaliplatin + 5-fu Serious Cure 2 1
Figure 1 
                  Sankey plot showing the relationships among patients’ characteristics.
Figure 1

Sankey plot showing the relationships among patients’ characteristics.

3.2 Adverse reaction and recurrence rate during chemotherapy

One case (2.22%) experienced fatigue (the patient experienced fatigue after three treatments, manifested as conscious fatigue and limb weakness, but the symptoms were mild and they spontaneously disappeared without intervention). Two cases (4.44%) experienced Grade 1 somnolence (the patient experienced somnolence after two treatments and manifested as excessive daytime sleep or sleep episodes). Two cases (4.44%) relapsed (1 cured patient relapsed into hiccup 3 days after drug discontinuation, and the another cured patient relapsed into hiccup 5 days after drug discontinuation) (Table 2).

Table 2

Characteristics of patients who had recurrence or adverse reactions

Patient number Age Sex Disease Grade PS score Chemotherapy regimen Degree of hiccup Relapse after baclofen withdrawal Fatigue Somnolence
24 72 Male Colorectal cancer cT3N + M1b ⅣB 2 Oxaliplatin + 5-fu + bevacizumab Moderate No No Yes
33 75 Male Colorectal cancer T3aN0M0 1 Oxaliplatin + capecitabine Moderate No No Yes
34 68 Male Esophageal cancer cT3N1M0 ⅢA 1 Paclitaxel Moderate Yes Yes No
42 75 Male Lung cancer cT4N2M0 ⅢB 1 Paclitaxel + carboplatin Moderate Yes No No

4 Discussion

Intractable hiccup, a common toxic and side effect of chemotherapy, is caused by multiple involuntary spastic contractions of the transverse diaphragm and intercostal muscles. Hiccup usually begins with sudden inspiration and ends with glottic closure. This rapid movement, accompanied by uncontrollable inhalation, causes the epiglottis to suddenly close the respiratory tract, thus making a short, loud sound [12,13]. Intractable hiccup refers to the case that the spasm persists for more than 48 h, which can lead to laceration of the test tube at the cardia part and the gastric fundus mucosa as the disease progresses, reducing the safety of chemotherapy [14,15].

Baclofen, a gamma-aminobutyric acid (GABA)-derived organism, inhibits the release of excitatory amino acids by exciting GABA-β receptor, thereby reducing the reflex potentials at single or multiple synapses in the spinal cord and between the posterior roots of the spinal cord, thereby playing a role in relaxing the skeletal muscle and relieving spasm [16,17]. Colorado and Decker [18] found that baclofen can help alleviate the symptoms of persistent hiccup in stroke patients with less adverse reactions. However, there is only a small sample size retrospective study on clinical hiccup caused by therapeutic tumor chemotherapy with baclofen. The clinical efficacy and safety of baclofen in the treatment of hiccup caused by malignant tumor chemotherapy are still unclear. At present, all the guidelines fail to take baclofen as a commonly used drug for the treatment of hiccup.

The results of this study showed that the total effective rate of baclofen in the treatment of hiccup caused by chemotherapy for malignant tumors was 100%, indicating that baclofen could effectively improve the treatment effect of patients with intractable hiccup caused by chemotherapy for malignant tumors. The reason for this analysis was that according to the research results of Zhang et al. [19], the total effective rate of 28 patients with intractable hiccup after primary liver cancer intervention was 92.86% (26/28) after treatment with baclofen. Similar to the research results, baclofen may play an important role in the treatment of intractable hiccup. Chemotherapy for malignant tumors can directly stimulate the vagus nerve, resulting in increased vagal function tension and diaphragmatic spasm. Ehret et al. [20] found that the incidence rate of intractable hiccup in patients with advanced cancer is about 3.9–4.98%, which belongs to the common toxic and side effects of chemotherapy in clinic. Intractable hiccup can seriously affect patients’ eating and rest, causing patients’ nutritional level to decrease, electrolyte disorders, depression, insomnia, and weakened immune function, thus affecting the patient’s treatment effect. At the same time, according to relevant research results, severe toxic and side effects can lead to patients’ resistance to chemotherapy, or even abandoning chemotherapy, thus affecting the efficacy of chemotherapy treatment of patients and shortening the survival time [21]. Baclofen, on the other hand, can act on GABA-β receptor of spinal motor neurons, inhibit synaptic reflex, and reduce excitatory synaptic sites as well as the reflex potential between hormone dorsal root and dorsal root, thereby playing a role in relaxing the skeletal muscle, improving clinical symptoms and chemotherapy comfort of patients [22].

The results of this study have shown that patients had a high rate of symptom relief after one dose of medication, indicating that baclofen has the characteristics of quick effect and strong drug effect. The reason for this analysis is that baclofen can be rapidly and completely absorbed through the gastrointestinal tract. According to the results of relevant studies, a single oral dose of 10, 20, and 30 mg baclofen can reach the peak plasma drug concentration in 0.5–1.5 h, thus exerting the drug effect rapidly [23].As one of the main inhibitory neurotransmitters in the brain and spinal cord of the central nervous system, GABA content is high, and GABA is a neurotransmitter for about 20–40% of synapses in the brain. By exciting the GABA-β receptor, baclofen inhibits the release of excitatory amino acids, and promotes the outflow of potassium and calcium ions in neurons to produce super-effect, reducing the transmission of synaptic reflex and reducing the activity of α-motor neurons, thereby relieving skeletal muscle spasm, reducing diaphragmatic muscle tension, improving the clinical symptoms of patients, improving the clinical efficacy, and reducing the frequency of drug administration [24]. Baclofen, a similar neurotransmitter with inhibitory effect on nerve conduction, is able to inhibit the single-synaptic and multi-synaptic reflex of the central nervous system, highly polarize the afferent end, and inhibit the central nervous system, thereby relieving the spasm caused by the damage of upper motor neurons, myoclonus, and muscle tremor, and reducing the frequency of hiccup attack [25].

In this study, there was only one case of fatigue and two cases of drowsiness. Besides, the patients’ adverse reaction symptoms were mild and they spontaneously disappeared without intervention. In previous literature, the adverse effects of oral baclofen could impact more than 25% of patients, and the symptoms usually included somnolence, nausea, and dizziness [11]. The rate of adverse reaction was lower in our study compared to published results, and the discrepancy could be explained as follows: (1) the subjects in our study were patients suffering from chemotherapy, and the homogeneous population could show less adverse events. (2) The dosage of baclofen was lower compared to other studies, in which the dosage usually exceeded 50 mg/day. It can be seen that the safety of baclofen treatment was high. The reason for this analysis was that the plasma elimination half-life of baclofen was 3–4 h, which was mostly excreted in prototype. Within 72 h, 75% of baclofen was excreted by kidney, with less drug retained in the body. At the same time, the main metabolite of baclofen is (p-chlorophenyl)-γ-hydroxybutyric acid without pharmacological activity, so the risk of adverse reactions is low. However, the safety of the specific drug needs further clinical research [26]. GABA is converted into baclofen by attaching p-chlorobenzene cluster to β carbon atom, so that through the blood–brain barrier, the skeletal muscle spasm caused by damaged pyramidal tract is relieved, the muscle tension is reduced, and the clinical symptoms of the patient are improved [27].

Our study had several strengths. We first conducted an explorative study on the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy, and offered original data for the following randomized controlled trials. In addition, to the best of our knowledge, this is the largest sample size available for a prospective study of baclofen in the treatment of intractable hiccup induced by chemotherapy for malignant tumors. However, limitation also existed in our study. First, our study was a single-center study, and enrolled patients may be biased. Second, our study had a small number of enrolled cases, and the distribution of patients’ gender was imbalanced. In addition, there was a lack of randomized control group. Since we aimed to provide an explorative result of baclofen treatment, the results of this study need to be verified by prospective randomized controlled trials with larger sample size.

In summary, baclofen has obvious effects and less side effects in the treatment of intractable hiccup caused by chemotherapy for malignant tumors.


tel: 13699549060; fax: 0791-86303391

Acknowledgements

The participation of all patients was highly appreciated.

  1. Funding information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (Grant numbers 81960571 and 81960468); Key Research and Development Project of Jiangxi province (Grant numbers 20192ACB70013 and 20181ACG70011), and Science and Technology Innovation Outstanding Young Talents Training Program of Jiangxi Province (Grant number 20192BCBL23023). The Provincial Natural Science Foundation of Jiangxi (Grant number 20181BAB205013).

  2. Author contributions: M.X.: conducted the study, accessed the data, and prepared the manuscript; M.F.: data acquisition and analysis; Y.M.: data acquisition and analysis; H.C.: data acquisition and analysis; L.H.: acted as the study guarantor, prepared the protocol, data acquisition, and prepared the artwork. All authors approved the final version of the manuscript.

  3. Conflict of interest: The authors declare that there are no conflicts of interest.

  4. Data availability statement: The datasets could be available upon reasonable requests from corresponding author.

References

[1] Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–48.10.1158/1078-0432.CCR-19-3492Search in Google Scholar PubMed PubMed Central

[2] de Steur WO, van Amelsfoort RM, Hartgrink HH, Putter H, Meershoek-Klein Kranenbarg E, van Grieken NCT, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol. 2021;32(3):360–7.10.1016/j.annonc.2020.11.004Search in Google Scholar PubMed

[3] Simsek Bagir G, Civi S, Kardes O, Kayaselcuk F, Ertorer ME. Stubborn hiccups as a sign of massive apoplexy in a naive acromegaly patient with pituitary macroadenoma. Endocrinol Diabetes Metab Case Rep. 2017;2017:17-0044.10.1530/EDM-17-0044Search in Google Scholar PubMed PubMed Central

[4] Ouyang X, Qu R, Hu B, Wang Y, Yao F, Lv B, et al. Is metoclopramide beneficial for the postpyloric placement of nasoenteric tubes? A systematic review and meta-analysis of randomized controlled trials. Nutr Clin Pract. 2022;37(2):316–27.10.1002/ncp.10725Search in Google Scholar PubMed PubMed Central

[5] Neumann J, Seidler T, Fehse C, Marusakova M, Hofmann B, Gergs U. Cardiovascular effects of metoclopramide and domperidone on human 5-HT4-serotonin-receptors in transgenic mice and in human atrial preparations. Eur J Pharmacol. 2021;901:174074.10.1016/j.ejphar.2021.174074Search in Google Scholar PubMed

[6] Snyder SD, Williams A, Mitchell M, Kneebusch J. Use of intramuscular chlorpromazine versus intramuscular olanzapine for the management of acute agitation and aggression in youth. J Pediatr Pharmacol Ther. 2021;26(1):33–41.10.5863/1551-6776-26.1.33Search in Google Scholar PubMed PubMed Central

[7] Zhang Y, Jiang X, Wang Z, He M, Lv Z, Yuan Q, et al. Efficacy of acupuncture for persistent and intractable hiccups: A protocol for systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2021;100(8):e24879.10.1097/MD.0000000000024879Search in Google Scholar PubMed PubMed Central

[8] Yu Y, Wen S, Wang S, Shi C, Ding H, Qiu Z, et al. Reflux characteristics in patients with gastroesophageal reflux-related chronic cough complicated by laryngopharyngeal reflux. Ann Transl Med. 2019;7(20):529.10.21037/atm.2019.09.162Search in Google Scholar PubMed PubMed Central

[9] ZT Z. Gastroenterology (3rd edn). Beijing: People ‘s Health Publishing House; 2000.Search in Google Scholar

[10] Chow R, Bruera E, Temel JS, Krishnan M, Im J, Lock M. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Support Care Cancer. 2020;28(5):2071–8.10.1007/s00520-019-05261-7Search in Google Scholar PubMed

[11] Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen. J Rehabil Med. 2017;49(3):193–203.10.2340/16501977-2211Search in Google Scholar PubMed

[12] Mustafa R, Neth BJ, Stitt D. Bilateral vagus nerve enhancement in a patient with leptomeningeal lymphoplasmacytic lymphoma presenting with intractable hiccups. JAMA Neurol. 2021;78(4):493–4.10.1001/jamaneurol.2020.4830Search in Google Scholar PubMed

[13] Wu JP, An JX, Qian XY, Wang Y. Successful treatment of idiopathic intractable hiccup with cisatracurium under intravenous general anesthesia: A case report. A A Pract. 2018;10(7):171–2.10.1213/XAA.0000000000000651Search in Google Scholar PubMed

[14] Dinoto A, Bosco A, Sartori A, Bratina A, Bellavita G, Pasquin F, et al. Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies. J Neuroimmunol. 2021;352:577488.10.1016/j.jneuroim.2021.577488Search in Google Scholar PubMed

[15] Patoli D, Chan RC, Tung A, Rana M. Successful left phrenic nerve block for intractable hiccups in a patient with LVAD-induced diaphragmatic irritation. J Cardiothorac Vasc Anesth. 2022;36(8 Pt A):2544–7.10.1053/j.jvca.2021.07.044Search in Google Scholar PubMed

[16] Agabio R, Baldwin DS, Amaro H, Leggio L, Sinclair JMA. The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;125:296–313.10.1016/j.neubiorev.2020.12.030Search in Google Scholar PubMed

[17] Kudva A, Abraham ME, Gold J, Patel NA, Gendreau JL, Herschman Y, et al. Intrathecal baclofen, selective dorsal rhizotomy, and extracorporeal shockwave therapy for the treatment of spasticity in cerebral palsy: A systematic review. Neurosurg Rev. 2021;44(6):3209–28.10.1007/s10143-021-01550-0Search in Google Scholar PubMed

[18] Colorado B, Decker G. Persistent hiccups after an epidural steroid injection successfully treated with baclofen: A case report. PM R. 2017;9(12):1290–3.10.1016/j.pmrj.2017.04.013Search in Google Scholar PubMed

[19] Zhang SK, Gao WB, Liu Y, He H. Therapeutic effect of cervical Jiaji electroacupuncture on postoperative intractable hiccup of liver neoplasms. Zhonghua Zhong Liu Za Zhi. 2018;40(2):138–40.Search in Google Scholar

[20] Ehret C, Young C, Ellefson CJ, Aase LA, Jatoi A. Frequency and symptomatology of hiccups in patients with cancer: Using an on-line medical community to better understand the patient experience. Am J Hosp Palliat Care. 2022;39(2):147–51.10.1177/10499091211006923Search in Google Scholar PubMed

[21] Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S, et al. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol. 2020;16(11):1109–24.10.1080/17425255.2020.1815705Search in Google Scholar PubMed PubMed Central

[22] Ozturk O, Yavuz E, Yazicioglu B, Uzuner B. Treatment of resistant idiopathic hiccups with pulse radio frequency on phrenic nerve and gabapentin: A case report. Niger J Clin Pract. 2017;20(7):910–3.10.4103/1119-3077.212438Search in Google Scholar

[23] Straus C, Teulier M, Morel S, Wattiez N, Hajage D, Giboin C, et al. Baclofen destabilises breathing during sleep in healthy humans: A randomised, controlled, double-blind crossover trial. Br J Clin Pharmacol. 2021;87(4):1814–23.10.1111/bcp.14569Search in Google Scholar PubMed

[24] Wen J, Bao J. Improved fermentative gamma-aminobutyric acid production by secretory expression of glutamate decarboxylase by Corynebacterium glutamicum. J Biotechnol. 2021;331:19–25.10.1016/j.jbiotec.2021.03.003Search in Google Scholar PubMed

[25] Hleihil M, Vaas M, Bhat MA, Balakrishnan K, Benke D. Sustained baclofen-induced activation of GABA B receptors after cerebral ischemia restores receptor expression and function and limits progressing loss of neurons. Front Mol Neurosci. 2021;14:726133.10.3389/fnmol.2021.726133Search in Google Scholar PubMed PubMed Central

[26] Echeverry-Alzate V, Jeanblanc J, Sauton P, Bloch V, Labat L, Soichot M, et al. Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side. Addict Biol. 2021;26(2):e12892.10.1111/adb.12892Search in Google Scholar PubMed

[27] Truong V, Cheng PZ, Lee HC, Lane TJ, Hsu TY, Duncan NW. Occipital gamma-aminobutyric acid and glutamate-glutamine alterations in major depressive disorder: An MRS study and meta-analysis. Psychiatry Res Neuroimaging. 2021;308:111238.10.1016/j.pscychresns.2020.111238Search in Google Scholar PubMed

Received: 2022-10-29
Revised: 2023-01-07
Accepted: 2023-01-20
Published Online: 2023-03-08

© 2023 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Articles
  2. Exosomes derived from mesenchymal stem cells overexpressing miR-210 inhibits neuronal inflammation and contribute to neurite outgrowth through modulating microglia polarization
  3. Current situation of acute ST-segment elevation myocardial infarction in a county hospital chest pain center during an epidemic of novel coronavirus pneumonia
  4. circ-IARS depletion inhibits the progression of non-small-cell lung cancer by circ-IARS/miR-1252-5p/HDGF ceRNA pathway
  5. circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma
  6. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
  7. Up-regulation of collagen type V alpha 2 (COL5A2) promotes malignant phenotypes in gastric cancer cell via inducing epithelial–mesenchymal transition (EMT)
  8. Inhibition of TERC inhibits neural apoptosis and inflammation in spinal cord injury through Akt activation and p-38 inhibition via the miR-34a-5p/XBP-1 axis
  9. 3D-printed polyether-ether-ketone/n-TiO2 composite enhances the cytocompatibility and osteogenic differentiation of MC3T3-E1 cells by downregulating miR-154-5p
  10. Propofol-mediated circ_0000735 downregulation restrains tumor growth by decreasing integrin-β1 expression in non-small cell lung cancer
  11. PVT1/miR-16/CCND1 axis regulates gastric cancer progression
  12. Silencing of circ_002136 sensitizes gastric cancer to paclitaxel by targeting the miR-16-5p/HMGA1 axis
  13. Short-term outcomes after simultaneous gastrectomy plus cholecystectomy in gastric cancer: A pooling up analysis
  14. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways
  15. Molecular mechanism by which the Notch signaling pathway regulates autophagy in a rat model of pulmonary fibrosis in pigeon breeder’s lung
  16. lncRNA TPT1-AS1 promotes cell migration and invasion in esophageal squamous-cell carcinomas by regulating the miR-26a/HMGA1 axis
  17. SIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis
  18. Glycoprotein non-metastatic melanoma B interacts with epidermal growth factor receptor to regulate neural stem cell survival and differentiation
  19. Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
  20. Association of osteoporosis and skeletal muscle loss with serum type I collagen carboxyl-terminal peptide β glypeptide: A cross-sectional study in elder Chinese population
  21. circ_0000376 knockdown suppresses non-small cell lung cancer cell tumor properties by the miR-545-3p/PDPK1 pathway
  22. Delivery in a vertical birth chair supported by freedom of movement during labor: A randomized control trial
  23. UBE2J1 knockdown promotes cell apoptosis in endometrial cancer via regulating PI3K/AKT and MDM2/p53 signaling
  24. Metabolic resuscitation therapy in critically ill patients with sepsis and septic shock: A pilot prospective randomized controlled trial
  25. Lycopene ameliorates locomotor activity and urinary frequency induced by pelvic venous congestion in rats
  26. UHRF1-induced connexin26 methylation is involved in hearing damage triggered by intermittent hypoxia in neonatal rats
  27. LINC00511 promotes melanoma progression by targeting miR-610/NUCB2
  28. Ultra-high-performance liquid chromatography-tandem mass spectrometry analysis of serum metabolomic characteristics in people with different vitamin D levels
  29. Role of Jumonji domain-containing protein D3 and its inhibitor GSK-J4 in Hashimoto’s thyroiditis
  30. circ_0014736 induces GPR4 to regulate the biological behaviors of human placental trophoblast cells through miR-942-5p in preeclampsia
  31. Monitoring of sirolimus in the whole blood samples from pediatric patients with lymphatic anomalies
  32. Effects of osteogenic growth peptide C-terminal pentapeptide and its analogue on bone remodeling in an osteoporosis rat model
  33. A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma
  34. WGCNA-based identification of potential targets and pathways in response to treatment in locally advanced breast cancer patients
  35. Radiomics model using preoperative computed tomography angiography images to differentiate new from old emboli of acute lower limb arterial embolism
  36. Dysregulated lncRNAs are involved in the progress of myocardial infarction by constructing regulatory networks
  37. Single-arm trial to evaluate the efficacy and safety of baclofen in treatment of intractable hiccup caused by malignant tumor chemotherapy
  38. Genetic polymorphisms of MRPS30-DT and NINJ2 may influence lung cancer risk
  39. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
  40. Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma
  41. Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis
  42. CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p
  43. Exosomal miR-93-5p regulated the progression of osteoarthritis by targeting ADAMTS9
  44. Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells
  45. HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway
  46. The association between sleep duration, quality, and nonalcoholic fatty liver disease: A cross-sectional study
  47. Myostatin silencing inhibits podocyte apoptosis in membranous nephropathy through Smad3/PKA/NOX4 signaling pathway
  48. A novel long noncoding RNA AC125257.1 facilitates colorectal cancer progression by targeting miR-133a-3p/CASC5 axis
  49. Impact of omicron wave and associated control measures in Shanghai on health management and psychosocial well-being of patients with chronic conditions
  50. Clinicopathological characteristics and prognosis of young patients aged ≤45 years old with non-small cell lung cancer
  51. TMT-based comprehensive proteomic profiling identifies serum prognostic signatures of acute myeloid leukemia
  52. The dose limits of teeth protection for patients with nasopharyngeal carcinoma undergoing radiotherapy based on the early oral health-related quality of life
  53. miR-30b-5p targeting GRIN2A inhibits hippocampal damage in epilepsy
  54. Long non-coding RNA AL137789.1 promoted malignant biological behaviors and immune escape of pancreatic carcinoma cells
  55. IRF6 and FGF1 polymorphisms in non-syndromic cleft lip with or without cleft palate in the Polish population
  56. Comprehensive analysis of the role of SFXN family in breast cancer
  57. Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy
  58. Silencing of long noncoding RNA MIAT inhibits the viability and proliferation of breast cancer cells by promoting miR-378a-5p expression
  59. AG1024, an IGF-1 receptor inhibitor, ameliorates renal injury in rats with diabetic nephropathy via the SOCS/JAK2/STAT pathway
  60. Downregulation of KIAA1199 alleviated the activation, proliferation, and migration of hepatic stellate cells by the inhibition of epithelial–mesenchymal transition
  61. Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment
  62. Inhibition of glycolysis represses the growth and alleviates the endoplasmic reticulum stress of breast cancer cells by regulating TMTC3
  63. The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma
  64. Tectorigenin alleviates the apoptosis and inflammation in spinal cord injury cell model through inhibiting insulin-like growth factor-binding protein 6
  65. Ultrasound examination supporting CT or MRI in the evaluation of cervical lymphadenopathy in patients with irradiation-treated head and neck cancer
  66. F-box and WD repeat domain containing 7 inhibits the activation of hepatic stellate cells by degrading delta-like ligand 1 to block Notch signaling pathway
  67. Knockdown of circ_0005615 enhances the radiosensitivity of colorectal cancer by regulating the miR-665/NOTCH1 axis
  68. Long noncoding RNA Mhrt alleviates angiotensin II-induced cardiac hypertrophy phenotypes by mediating the miR-765/Wnt family member 7B pathway
  69. Effect of miR-499-5p/SOX6 axis on atrial fibrosis in rats with atrial fibrillation
  70. Cholesterol induces inflammation and reduces glucose utilization
  71. circ_0004904 regulates the trophoblast cell in preeclampsia via miR-19b-3p/ARRDC3 axis
  72. NECAB3 promotes the migration and invasion of liver cancer cells through HIF-1α/RIT1 signaling pathway
  73. The poor performance of cardiovascular risk scores in identifying patients with idiopathic inflammatory myopathies at high cardiovascular risk
  74. miR-2053 inhibits the growth of ovarian cancer cells by downregulating SOX4
  75. Nucleophosmin 1 associating with engulfment and cell motility protein 1 regulates hepatocellular carcinoma cell chemotaxis and metastasis
  76. α-Hederin regulates macrophage polarization to relieve sepsis-induced lung and liver injuries in mice
  77. Changes of microbiota level in urinary tract infections: A meta-analysis
  78. Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
  79. Falls during oxaliplatin-based chemotherapy for gastrointestinal malignancies – (lessons learned from) a prospective study
  80. Outcomes of low-risk birth care during the Covid-19 pandemic: A cohort study from a tertiary care center in Lithuania
  81. Vitamin D protects intestines from liver cirrhosis-induced inflammation and oxidative stress by inhibiting the TLR4/MyD88/NF-κB signaling pathway
  82. Integrated transcriptome analysis identifies APPL1/RPS6KB2/GALK1 as immune-related metastasis factors in breast cancer
  83. Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme
  84. Circular RNA Circ_0038467 promotes the maturation of miRNA-203 to increase lipopolysaccharide-induced apoptosis of chondrocytes
  85. An economic evaluation of fine-needle cytology as the primary diagnostic tool in the diagnosis of lymphadenopathy
  86. Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
  87. Network pharmacology combined with molecular docking and experimental validation to reveal the pharmacological mechanism of naringin against renal fibrosis
  88. PTPN12 down-regulated by miR-146b-3p gene affects the malignant progression of laryngeal squamous cell carcinoma
  89. miR-141-3p accelerates ovarian cancer progression and promotes M2-like macrophage polarization by targeting the Keap1-Nrf2 pathway
  90. lncRNA OIP5-AS1 attenuates the osteoarthritis progression in IL-1β-stimulated chondrocytes
  91. Overexpression of LINC00607 inhibits cell growth and aggressiveness by regulating the miR-1289/EFNA5 axis in non-small-cell lung cancer
  92. Subjective well-being in informal caregivers during the COVID-19 pandemic
  93. Nrf2 protects against myocardial ischemia-reperfusion injury in diabetic rats by inhibiting Drp1-mediated mitochondrial fission
  94. Unfolded protein response inhibits KAT2B/MLKL-mediated necroptosis of hepatocytes by promoting BMI1 level to ubiquitinate KAT2B
  95. Bladder cancer screening: The new selection and prediction model
  96. circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
  97. Prone position effect in intensive care patients with SARS-COV-2 pneumonia
  98. Clinical observation on the efficacy of Tongdu Tuina manipulation in the treatment of primary enuresis in children
  99. Dihydroartemisinin ameliorates cerebral I/R injury in rats via regulating VWF and autophagy-mediated SIRT1/FOXO1 pathway
  100. Knockdown of circ_0113656 assuages oxidized low-density lipoprotein-induced vascular smooth muscle cell injury through the miR-188-3p/IGF2 pathway
  101. Low Ang-(1–7) and high des-Arg9 bradykinin serum levels are correlated with cardiovascular risk factors in patients with COVID-19
  102. Effect of maternal age and body mass index on induction of labor with oral misoprostol for premature rupture of membrane at term: A retrospective cross-sectional study
  103. Potential protective effects of Huanglian Jiedu Decoction against COVID-19-associated acute kidney injury: A network-based pharmacological and molecular docking study
  104. Clinical significance of serum MBD3 detection in girls with central precocious puberty
  105. Clinical features of varicella-zoster virus caused neurological diseases detected by metagenomic next-generation sequencing
  106. Collagen treatment of complex anorectal fistula: 3 years follow-up
  107. LncRNA CASC15 inhibition relieves renal fibrosis in diabetic nephropathy through down-regulating SP-A by sponging to miR-424
  108. Efficacy analysis of empirical bismuth quadruple therapy, high-dose dual therapy, and resistance gene-based triple therapy as a first-line Helicobacter pylori eradication regimen – An open-label, randomized trial
  109. SMOC2 plays a role in heart failure via regulating TGF-β1/Smad3 pathway-mediated autophagy
  110. A prospective cohort study of the impact of chronic disease on fall injuries in middle-aged and older adults
  111. circRNA THBS1 silencing inhibits the malignant biological behavior of cervical cancer cells via the regulation of miR-543/HMGB2 axis
  112. hsa_circ_0000285 sponging miR-582-3p promotes neuroblastoma progression by regulating the Wnt/β-catenin signaling pathway
  113. Long non-coding RNA GNAS-AS1 knockdown inhibits proliferation and epithelial–mesenchymal transition of lung adenocarcinoma cells via the microRNA-433-3p/Rab3A axis
  114. lncRNA UCA1 regulates miR-132/Lrrfip1 axis to promote vascular smooth muscle cell proliferation
  115. Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia
  116. Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene
  117. Anti-inflammatory effect of ApoE23 on Salmonella typhimurium-induced sepsis in mice
  118. Analysis of somatic mutations and key driving factors of cervical cancer progression
  119. Hsa_circ_0028007 regulates the progression of nasopharyngeal carcinoma through the miR-1179/SQLE axis
  120. Variations in sexual function after laparoendoscopic single-site hysterectomy in women with benign gynecologic diseases
  121. Effects of pharmacological delay with roxadustat on multi-territory perforator flap survival in rats
  122. Analysis of heroin effects on calcium channels in rat cardiomyocytes based on transcriptomics and metabolomics
  123. Risk factors of recurrent bacterial vaginosis among women of reproductive age: A cross-sectional study
  124. Alkbh5 plays indispensable roles in maintaining self-renewal of hematopoietic stem cells
  125. Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
  126. Correlation between microvessel maturity and ISUP grades assessed using contrast-enhanced transrectal ultrasonography in prostate cancer
  127. The protective effect of caffeic acid phenethyl ester in the nephrotoxicity induced by α-cypermethrin
  128. Norepinephrine alleviates cyclosporin A-induced nephrotoxicity by enhancing the expression of SFRP1
  129. Effect of RUNX1/FOXP3 axis on apoptosis of T and B lymphocytes and immunosuppression in sepsis
  130. The function of Foxp1 represses β-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity
  131. Risk model and validation of carbapenem-resistant Klebsiella pneumoniae infection in patients with cerebrovascular disease in the ICU
  132. Calycosin protects against chronic prostatitis in rats via inhibition of the p38MAPK/NF-κB pathway
  133. Pan-cancer analysis of the PDE4DIP gene with potential prognostic and immunotherapeutic values in multiple cancers including acute myeloid leukemia
  134. The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
  135. Circ-UBR4 regulates the proliferation, migration, inflammation, and apoptosis in ox-LDL-induced vascular smooth muscle cells via miR-515-5p/IGF2 axis
  136. Clinical characteristics of current COVID-19 rehabilitation outpatients in China
  137. Luteolin alleviates ulcerative colitis in rats via regulating immune response, oxidative stress, and metabolic profiling
  138. miR-199a-5p inhibits aortic valve calcification by targeting ATF6 and GRP78 in valve interstitial cells
  139. The application of iliac fascia space block combined with esketamine intravenous general anesthesia in PFNA surgery of the elderly: A prospective, single-center, controlled trial
  140. Elevated blood acetoacetate levels reduce major adverse cardiac and cerebrovascular events risk in acute myocardial infarction
  141. The effects of progesterone on the healing of obstetric anal sphincter damage in female rats
  142. Identification of cuproptosis-related genes for predicting the development of prostate cancer
  143. Lumican silencing ameliorates β-glycerophosphate-mediated vascular smooth muscle cell calcification by attenuating the inhibition of APOB on KIF2C activity
  144. Targeting PTBP1 blocks glutamine metabolism to improve the cisplatin sensitivity of hepatocarcinoma cells through modulating the mRNA stability of glutaminase
  145. A single center prospective study: Influences of different hip flexion angles on the measurement of lumbar spine bone mineral density by dual energy X-ray absorptiometry
  146. Clinical analysis of AN69ST membrane continuous venous hemofiltration in the treatment of severe sepsis
  147. Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: A systematic review and meta-analysis
  148. Construction of a ceRNA network to reveal a vascular invasion associated prognostic model in hepatocellular carcinoma
  149. A pan-cancer analysis of STAT3 expression and genetic alterations in human tumors
  150. A prognostic signature based on seven T-cell-related cell clustering genes in bladder urothelial carcinoma
  151. Pepsin concentration in oral lavage fluid of rabbit reflux model constructed by dilating the lower esophageal sphincter
  152. The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC
  153. Tanshinone IIA attenuates valvular interstitial cells’ calcification induced by oxidized low density lipoprotein via reducing endoplasmic reticulum stress
  154. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
  155. Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes
  156. Trial protocol: Feasibility of neuromodulation with connectivity-guided intermittent theta-burst stimulation for improving cognition in multiple sclerosis
  157. LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer
  158. Factors associated with gastrointestinal dysmotility in critically ill patients
  159. Mechanisms by which spinal cord stimulation intervenes in atrial fibrillation: The involvement of the endothelin-1 and nerve growth factor/p75NTR pathways
  160. Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics
  161. Silencing USP19 alleviates cigarette smoke extract-induced mitochondrial dysfunction in BEAS-2B cells by targeting FUNDC1
  162. Menstrual irregularities associated with COVID-19 vaccines among women in Saudi Arabia: A survey during 2022
  163. Ferroptosis involves in Schwann cell death in diabetic peripheral neuropathy
  164. The effect of AQP4 on tau protein aggregation in neurodegeneration and persistent neuroinflammation after cerebral microinfarcts
  165. Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance
  166. Analysis of clinical characteristics in proximal and distal reflux monitoring among patients with gastroesophageal reflux disease
  167. Exosomal circ-0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients
  168. Upregulated microRNA-429 confers endometrial stromal cell dysfunction by targeting HIF1AN and regulating the HIF1A/VEGF pathway
  169. Bibliometrics and knowledge map analysis of ultrasound-guided regional anesthesia
  170. Knockdown of NUPR1 inhibits angiogenesis in lung cancer through IRE1/XBP1 and PERK/eIF2α/ATF4 signaling pathways
  171. D-dimer trends predict COVID-19 patient’s prognosis: A retrospective chart review study
  172. WTAP affects intracranial aneurysm progression by regulating m6A methylation modification
  173. Using of endoscopic polypectomy in patients with diagnosed malignant colorectal polyp – The cross-sectional clinical study
  174. Anti-S100A4 antibody administration alleviates bronchial epithelial–mesenchymal transition in asthmatic mice
  175. Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma
  176. Prevalence and antibiogram of bacteria causing urinary tract infection among patients with chronic kidney disease
  177. Reactive oxygen species within the vaginal space: An additional promoter of cervical intraepithelial neoplasia and uterine cervical cancer development?
  178. Identification of disulfidptosis-related genes and immune infiltration in lower-grade glioma
  179. A new technique for uterine-preserving pelvic organ prolapse surgery: Laparoscopic rectus abdominis hysteropexy for uterine prolapse by comparing with traditional techniques
  180. Self-isolation of an Italian long-term care facility during COVID-19 pandemic: A comparison study on care-related infectious episodes
  181. A comparative study on the overlapping effects of clinically applicable therapeutic interventions in patients with central nervous system damage
  182. Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up
  183. The diagnostic accuracy of touch imprint cytology for sentinel lymph node metastases of breast cancer: An up-to-date meta-analysis of 4,073 patients
  184. Mortality associated with Sjögren’s syndrome in the United States in the 1999–2020 period: A multiple cause-of-death study
  185. CircMMP11 as a prognostic biomarker mediates miR-361-3p/HMGB1 axis to accelerate malignant progression of hepatocellular carcinoma
  186. Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations
  187. KMT2A maintains stemness of gastric cancer cells through regulating Wnt/β-catenin signaling-activated transcriptional factor KLF11
  188. Evaluation of placental oxygenation by near-infrared spectroscopy in relation to ultrasound maturation grade in physiological term pregnancies
  189. The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
  190. Construction of immunogenic cell death-related molecular subtypes and prognostic signature in colorectal cancer
  191. Long-term prognostic value of high-sensitivity cardiac troponin-I in patients with idiopathic dilated cardiomyopathy
  192. Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients
  193. Integrative bioinformatics analysis reveals STAT2 as a novel biomarker of inflammation-related cardiac dysfunction in atrial fibrillation
  194. Adipose-derived stem cells repair radiation-induced chronic lung injury via inhibiting TGF-β1/Smad 3 signaling pathway
  195. Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
  196. lncRNA LENGA sponges miR-378 to promote myocardial fibrosis in atrial fibrillation
  197. Diagnostic value of urinary Tamm-Horsfall protein and 24 h urine osmolality for recurrent calcium oxalate stones of the upper urinary tract: Cross-sectional study
  198. The value of color Doppler ultrasonography combined with serum tumor markers in differential diagnosis of gastric stromal tumor and gastric cancer
  199. The spike protein of SARS-CoV-2 induces inflammation and EMT of lung epithelial cells and fibroblasts through the upregulation of GADD45A
  200. Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
  201. MiR-1278 targets CALD1 and suppresses the progression of gastric cancer via the MAPK pathway
  202. Metabolomic analysis of serum short-chain fatty acid concentrations in a mouse of MPTP-induced Parkinson’s disease after dietary supplementation with branched-chain amino acids
  203. Cimifugin inhibits adipogenesis and TNF-α-induced insulin resistance in 3T3-L1 cells
  204. Predictors of gastrointestinal complaints in patients on metformin therapy
  205. Prescribing patterns in patients with chronic obstructive pulmonary disease and atrial fibrillation
  206. A retrospective analysis of the effect of latent tuberculosis infection on clinical pregnancy outcomes of in vitro fertilization–fresh embryo transferred in infertile women
  207. Appropriateness and clinical outcomes of short sustained low-efficiency dialysis: A national experience
  208. miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD
  209. Clinical features and management of lymphoepithelial cyst
  210. Serum VEGF, high-sensitivity CRP, and cystatin-C assist in the diagnosis of type 2 diabetic retinopathy complicated with hyperuricemia
  211. ENPP1 ameliorates vascular calcification via inhibiting the osteogenic transformation of VSMCs and generating PPi
  212. Significance of monitoring the levels of thyroid hormone antibodies and glucose and lipid metabolism antibodies in patients suffer from type 2 diabetes
  213. The causal relationship between immune cells and different kidney diseases: A Mendelian randomization study
  214. Interleukin 33, soluble suppression of tumorigenicity 2, interleukin 27, and galectin 3 as predictors for outcome in patients admitted to intensive care units
  215. Identification of diagnostic immune-related gene biomarkers for predicting heart failure after acute myocardial infarction
  216. Long-term administration of probiotics prevents gastrointestinal mucosal barrier dysfunction in septic mice partly by upregulating the 5-HT degradation pathway
  217. miR-192 inhibits the activation of hepatic stellate cells by targeting Rictor
  218. Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis
  219. Review Articles
  220. Prenatal diagnosis of fetal defects and its implications on the delivery mode
  221. Electromagnetic fields exposure on fetal and childhood abnormalities: Systematic review and meta-analysis
  222. Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae
  223. Saddle pulmonary embolism in the setting of COVID-19 infection: A systematic review of case reports and case series
  224. Vitamin C and epigenetics: A short physiological overview
  225. Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
  226. Aspirin versus LMWH for VTE prophylaxis after orthopedic surgery
  227. Mechanism of rhubarb in the treatment of hyperlipidemia: A recent review
  228. Surgical management and outcomes of traumatic global brachial plexus injury: A concise review and our center approach
  229. The progress of autoimmune hepatitis research and future challenges
  230. METTL16 in human diseases: What should we do next?
  231. New insights into the prevention of ureteral stents encrustation
  232. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature
  233. Case Reports
  234. Mycobacterium xenopi infection of the kidney and lymph nodes: A case report
  235. Genetic mutation of SLC6A20 (c.1072T > C) in a family with nephrolithiasis: A case report
  236. Chronic hepatitis B complicated with secondary hemochromatosis was cured clinically: A case report
  237. Liver abscess complicated with multiple organ invasive infection caused by hematogenous disseminated hypervirulent Klebsiella pneumoniae: A case report
  238. Urokinase-based lock solutions for catheter salvage: A case of an upcoming kidney transplant recipient
  239. Two case reports of maturity-onset diabetes of the young type 3 caused by the hepatocyte nuclear factor 1α gene mutation
  240. Immune checkpoint inhibitor-related pancreatitis: What is known and what is not
  241. Does total hip arthroplasty result in intercostal nerve injury? A case report and literature review
  242. Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi – Case report and literature review
  243. Synchronous triple primary gastrointestinal malignant tumors treated with laparoscopic surgery: A case report
  244. CT-guided percutaneous microwave ablation combined with bone cement injection for the treatment of transverse metastases: A case report
  245. Malignant hyperthermia: Report on a successful rescue of a case with the highest temperature of 44.2°C
  246. Anesthetic management of fetal pulmonary valvuloplasty: A case report
  247. Rapid Communication
  248. Impact of COVID-19 lockdown on glycemic levels during pregnancy: A retrospective analysis
  249. Erratum
  250. Erratum to “Inhibition of miR-21 improves pulmonary vascular responses in bronchopulmonary dysplasia by targeting the DDAH1/ADMA/NO pathway”
  251. Erratum to: “Fer exacerbates renal fibrosis and can be targeted by miR-29c-3p”
  252. Retraction
  253. Retraction of “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
  254. Retraction of “circ_0062491 alleviates periodontitis via the miR-142-5p/IGF1 axis”
  255. Retraction of “miR-223-3p alleviates TGF-β-induced epithelial-mesenchymal transition and extracellular matrix deposition by targeting SP3 in endometrial epithelial cells”
  256. Retraction of “SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673/KIF21B axis”
  257. Retraction of “circRNA_0001679/miR-338-3p/DUSP16 axis aggravates acute lung injury”
  258. Retraction of “lncRNA ACTA2-AS1 inhibits malignant phenotypes of gastric cancer cells”
  259. Special issue Linking Pathobiological Mechanisms to Clinical Application for cardiovascular diseases
  260. Effect of cardiac rehabilitation therapy on depressed patients with cardiac insufficiency after cardiac surgery
  261. Special issue The evolving saga of RNAs from bench to bedside - Part I
  262. FBLIM1 mRNA is a novel prognostic biomarker and is associated with immune infiltrates in glioma
  263. Special Issue Computational Intelligence Methodologies Meets Recurrent Cancers - Part III
  264. Development of a machine learning-based signature utilizing inflammatory response genes for predicting prognosis and immune microenvironment in ovarian cancer
Downloaded on 9.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2023-0664/html
Scroll to top button